|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yam PC, Tong D and Law S: Comparisons of
sixth and seventh edition of the American Joint Cancer Committee
staging systems for esophageal cancer. Ann Surg Oncol. 21:583–588.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Enchev RI, Schulman BA and Peter M:
Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell
Biol. 16:30–44. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abidi N and Xirodimas DP: Regulation of
cancer-related pathways by protein NEDDylation and strategies for
the use of NEDD8 inhibitors in the clinic. Endocr Relat Cancer.
22:T55–T70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siergiejuk E, Scott DC, Schulman BA,
Hofmann K, Kurz T and Peter M: Cullin neddylation and
substrate-adaptors counteract SCF inhibition by the CAND1-like
protein Lag2 in Saccharomyces cerevisiae. EMBO J.
28:3845–3856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen P, Hu T, Liang Y, Li P, Chen X, Zhang
J, Ma Y, Hao Q, Wang J, Zhang P, et al: Neddylation inhibition
activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5
axis in human esophageal cancer cells. Clin Cancer Res.
22:4145–4157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hua W, Li C, Yang Z, Li L, Jiang Y, Yu G,
Zhu W, Liu Z, Duan S, Chu Y, et al: Suppression of glioblastoma by
targeting the overactivated protein neddylation pathway. Neuro
Oncol. 17:1333–1343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Wang M, Yu G, Chen P, Li H, Wei D,
Zhu J, Xie L, Jia H, Shi J, et al: Overactivated neddylation
pathway as a therapeutic target in lung cancer. J Natl Cancer Inst.
106:dju0832014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie P, Zhang M, He S, Lu K, Chen Y, Xing
G, Lu Y, Liu P, Li Y, Wang S, et al: The covalent modifier Nedd8 is
critical for the activation of Smurf1 ubiquitin ligase in
tumorigenesis. Nat Commun. 5:37332014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao Q, Yu GY, Shi JY, Li LH, Zhang WJ,
Wang ZC, Yang LX, Duan M, Zhao H, Wang XY, et al: Neddylation
pathway is up-regulated in human intrahepatic cholangiocarcinoma
and serves as a potential therapeutic target. Oncotarget.
5:7820–7832. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai
YC, Chang HC, Chou CT, Hsu CH, Hsieh JT, et al: MLN4924, a novel
protein neddylation inhibitor, suppresses proliferation and
migration of human urothelial carcinoma: In vitro and in vivo
studies. Cancer Lett. 363:127–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wan J, Zhu J, Li G and Zhang Z:
Radiosensitization of human colorectal cancer cells by MLN4924: An
inhibitor of NEDD8-activating enzyme. Technol Cancer Res Treat.
15:527–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lan H, Tang Z, Jin H and Sun Y:
Neddylation inhibitor MLN4924 suppresses growth and migration of
human gastric cancer cells. Sci Rep. 6:242182016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Luo Z, Pan Y, Wang W, Zhou X,
Jeong LS, Chu Y, Liu J and Jia L: Targeting protein neddylation
with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis
or senescence in human lymphoma cells. Cancer Biol Ther.
16:420–429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han K, Wang Q, Cao H, Qiu G, Cao J, Li X,
Wang J, Shen B and Zhang J: The NEDD8-activating enzyme inhibitor
MLN4924 induces G2 arrest and apoptosis in T-cell acute
lymphoblastic leukemia. Oncotarget. 7:23812–23824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bhatia S, Pavlick AC, Boasberg P, Thompson
JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ and Hamid O: A
phase I study of the investigational NEDD8-activating enzyme
inhibitor pevonedistat (TAK-924/MLN4924) in patients with
metastatic melanoma. Invest New Drugs. 34:439–449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shah JJ, Jakubowiak AJ, O'Connor OA,
Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K,
Hua Z, et al: Phase I study of the novel investigational
NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in
patients with relapsed/refractory multiple myeloma or lymphoma.
Clin Cancer Res. 22:34–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sarantopoulos J, Shapiro GI, Cohen RB,
Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD,
Faessel HM, et al: Phase I study of the investigational
NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in
patients with advanced solid tumors. Clin Cancer Res. 22:847–857.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nawrocki ST, Kelly KR, Smith PG, Espitia
CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M,
Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924
is a novel strategy to target cisplatin resistance in ovarian
cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jazaeri AA, Shibata E, Park J, Bryant JL,
Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ and
Dutta A: Overcoming platinum resistance in preclinical models of
ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer
Ther. 12:1958–1967. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin WC, Kuo KL, Shi CS, Wu JT, Hsieh JT,
Chang HC, Liao SM, Chou CT, Chiang CK, Chiu WS, et al: MLN4924, a
novel NEDD8-activating enzyme inhibitor, exhibits antitumor
activity and enhances cisplatin-induced cytotoxicity in human
cervical carcinoma: In vitro and in vivo study. Am J Cancer Res.
5:3350–3362. 2015.PubMed/NCBI
|
|
23
|
Wang X, Zhang W, Yan Z, Liang Y, Li L, Yu
X, Feng Y, Fu S, Zhang Y, Zhao H, et al: Radiosensitization by the
investigational NEDD8-activating enzyme inhibitor MLN4924
(pevonedistat) in hormone-resistant prostate cancer cells.
Oncotarget. 7:38380–38391. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT,
Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, et al: MLN4924
synergistically enhances cisplatin-induced cytotoxicity via JNK and
Bcl-xL pathways in human urothelial carcinoma. Sci Rep.
5:169482015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen P, Hu T, Liang Y, Li P, Chen X, Zhang
J, Ma Y, Hao Q, Wang J, Zhang P, et al: Neddylation inhibition
activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5
axis in human esophageal cancer cells. Clin Cancer Res.
22:4145–4157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sarcar B, Kahali S, Prabhu AH, Shumway SD,
Xu Y, Demuth T and Chinnaiyan P: Targeting radiation-induced G(2)
checkpoint activation with the Wee-1 inhibitor MK-1775 in
glioblastoma cell lines. Mol Cancer Ther. 10:2405–2414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fischle W, Tseng BS, Dormann HL,
Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF, Funabiki H and
Allis CD: Regulation of HP1-chromatin binding by histone H3
methylation and phosphorylation. Nature. 438:1116–1122. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Emanuele MJ, Elia AE, Xu Q, Thoma CR,
Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, et al: Global
identification of modular cullin-RING ligase substrates. Cell.
147:459–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oladghaffari M, Islamian JP, Baradaran B
and Monfared AS: MLN4924 therapy as a novel approach in cancer
treatment modalities. J Chemother. 28:74–82. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paiva C, Godbersen JC, Berger A, Brown JR
and Danilov AV: Targeting neddylation induces DNA damage and
checkpoint activation and sensitizes chronic lymphocytic leukemia B
cells to alkylating agents. Cell Death Dis. 6:e18072015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao Y, Morgan MA and Sun Y: Targeting
Neddylation pathways to inactivate cullin-RING ligases for
anticancer therapy. Antioxid Redox Signal. 21:2383–2400. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stark GR and Taylor WR: Analyzing the G2/M
checkpoint. Methods Mol Biol. 280:51–82. 2004.PubMed/NCBI
|
|
33
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers. 3:1351–1371. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Sousa GF, Mde A Lima, Custodio DF,
Freitas VM and Monteiro G: Chemogenomic study of carboplatin in
saccharomyces cerevisiae: Inhibition of the NEDDylation process
overcomes cellular resistance mediated by HuR and cullin proteins.
PLoS One. 10:e01453772015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pan WW, Zhou JJ, Yu C, Xu Y, Guo LJ, Zhang
HY, Zhou D, Song FZ and Fan HY: Ubiquitin E3 ligase
CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian
surface epithelial cancer. J Biol Chem. 288:29680–29691. 2013.
View Article : Google Scholar : PubMed/NCBI
|
